News
-
-
PRESS RELEASE
Formycon AG: Subscription period for 2025/2029 corporate bond has started
Formycon AG announces the start of the subscription period for the 2025/2029 corporate bond with a target volume of EUR 50 million, featuring a variable interest rate. Investors can submit subscription offers until June 27, 2025 -
-
-
-
PRESS RELEASE
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
Formycon AG plans EUR 50 million senior unsecured bond issuance for company growth. Joint Lead Managers: IKB Deutsche Industriebank AG, Pareto Securities AS -
-
-
-
PRESS RELEASE
Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
Formycon and Fresenius Kabi announce commercial launch of FYB202/Otulfi ustekinumab biosimilar in Canada, expanding treatment options for chronic autoimmune diseases
